ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sanofi b.v. - agalsidaza beta - fabryjeva bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - zdravilo fabrazyme je indicirano za dolgoročno nadomestno encimsko dajanje pri bolnikih s potrjeno diagnozo fabryjeve bolezni (pomanjkanje α-galaktozidaze-a).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sanofi b.v. - laronidaza - mucopolisaharidoza i - drugi zdravljene bolezni prebavil in presnove izdelki, - aldurazyme je označen za dolgoročno encim nadomestno zdravljenje pri bolnikih s potrjeno diagnozo mucopolysaccharidosis i (mps i; alfa-l-iduronidase pomanjkljivost) za zdravljenje nonneurological manifestacije bolezni.

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - klindamicin - gel - klindamicin 10 mg / 1 g - klindamicin

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer luxembourg sarl - klindamicin - dermalna emulzija - klindamicin 10 mg / 1 ml - klindamicin

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - rituksimab - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastična sredstva - blitzima je navedeno v odraslih za naslednje indikacije:ne-hodgkinova limfomi (nhl)blitzima je primerna za zdravljenje predhodno nezdravljenih bolnikov s fazo iii-iv folikularni limfom v kombinaciji s kemoterapijo. blitzima vzdrževanje terapija je primerna za zdravljenje folikularni limfom bolniki odzivajo na indukcijsko zdravljenje. blitzima monotherapy je indiciran za zdravljenje bolnikov z faza iii-iv folikularni limfom, ki so kemo-odporne ali so v drugi ali poznejši ponovitve po kemoterapijo. blitzima je indiciran za zdravljenje bolnikov z cd20 pozitivni razpršenih velika b celic non-hodgkinova limfom v kombinaciji z chop (ciklofosfamid, doxorubicin, vincristine, prednizolon) kemoterapijo. kronično limfocitno levkemijo (cll)blitzima v kombinaciji s kemoterapijo je indiciran za zdravljenje bolnikov z predhodno nezdravljenih in relapsed/ognjevzdržni cll. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z blitzima ali bolniki, ognjevzdržni, da prejšnji blitzima plus kemoterapijo.

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastična sredstva - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z rituksimabom ali bolniki, ognjevzdržni, da prejšnji rituksimabom plus kemoterapijo. glej oddelek 5. 1 za nadaljnje informacije. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituksimabom je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

sandoz gmbh - rituksimab - lymphoma, non-hodgkin; arthritis, rheumatoid; leukemia, lymphocytic, chronic, b-cell; wegener granulomatosis; microscopic polyangiitis; pemphigus - antineoplastična sredstva - rixathon is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)rixathon is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. rixathon maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. rixathon monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. rixathon is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. rixathon in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). kronično limfocitno levkemijo (cll)rixathon v kombinaciji s kemoterapijo je indiciran za zdravljenje bolnikov z predhodno nezdravljenih in relapsed/ognjevzdržni kronično limfocitno levkemijo. samo omejeni so na voljo podatki o učinkovitosti in varnosti za bolnike predhodno zdravljenih z monoklonalna protitelesa, vključno z rituksimabom ali bolniki, ognjevzdržni, da prejšnji rituksimabom plus kemoterapijo. glej oddelek 5. 1 za nadaljnje informacije. revmatoidni arthritisrixathon v kombinaciji z metotreksatom je indiciran za zdravljenje odraslih bolnikov s hudo aktivnega revmatoidnega artritisa, ki so imeli z neustreznim odzivom ali nestrpnosti do drugih bolezni spreminjanje anti-revmatičnih zdravila (dmard) vključno z enim ali več tumor nekroze faktor (tnf) inhibitor terapije. rituksimabom je dokazano, da zmanjša stopnjo napredovanja skupno škodo, merjeno z x-ray in izboljšati telesno funkcijo, če bi imeli v kombinaciji z metotreksatom. granulomatosis with polyangiitis and microscopic polyangiitisrixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). rixathon, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisrixathon is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

makrogol; natrijev sulfat, brezvodni; natrijev klorid; kalijev klorid - prašek za peroralno raztopino - makrogol 100 g / 1 vrečica  natrijev sulfat, brezvodni9 g / 1 vrečica  natrijev klorid2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; natrijev sulfat, brezvodni 9 g / 1 vrečica  natrijev klorid2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; natrijev klorid 2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; kalijev klorid - makrogol, kombinacije

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

makrogol; natrijev sulfat, brezvodni; natrijev klorid; kalijev klorid - prašek za peroralno raztopino - makrogol 100 g / 1 vrečica  natrijev sulfat, brezvodni9 g / 1 vrečica  natrijev klorid2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; natrijev sulfat, brezvodni 9 g / 1 vrečica  natrijev klorid2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; natrijev klorid 2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; kalijev klorid - makrogol, kombinacije

স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

makrogol; natrijev sulfat, brezvodni; natrijev klorid; kalijev klorid - prašek za peroralno raztopino - makrogol 100 g / 1 vrečica  natrijev sulfat, brezvodni9 g / 1 vrečica  natrijev klorid2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; natrijev sulfat, brezvodni 9 g / 1 vrečica  natrijev klorid2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; natrijev klorid 2 g / 1 vrečica  kalijev klorid1 g / 1 vrečica; kalijev klorid - makrogol, kombinacije